Prescription medication · PDE4 Inhibitor (Topical)
crisaborole
Also sold as Eucrisa. Eucrisa treats mild to moderate atopic dermatitis, also known as eczema.
Data updated 2026-05-15
- 9,400
- FDA reportsLightly reported
- $10.30
- Brand price (NADAC)
crisaborole (Eucrisa) is a prescription PDE4 Inhibitor (Topical). Eucrisa treats mild to moderate atopic dermatitis, also known as eczema.
Eucrisa is a medicine used on the skin to treat eczema. It helps reduce swelling and itching.
Verify with FDA → · CMS NADAC pricing →
Drug Pricing (NADAC)
Brand Price
$10.30/unit
Generic Available
No
ANACOR PHARMS INC
Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →
What it does
Eucrisa treats mild to moderate atopic dermatitis, also known as eczema.
Common side effects
Pain where you put the medicine
Key warnings
If you have a hypersensitivity reaction, stop using Eucrisa right away.
The sections below are summarized in plain English from crisaborole's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Eucrisa contains crisaborole, which is a phosphodiesterase-4 (PDE4) inhibitor. This medicine works by blocking PDE4. Blocking PDE4 reduces inflammation in the skin, which helps to relieve eczema symptoms.
Side Effects (from patient reports)
Based on 9,400 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for crisaborole, by number of reports
- Application Site Pain
Application Site Pain
1,415 reports
- Burning Sensation
Burning Sensation
985 reports
- Condition Aggravated
Condition Aggravated
699 reports
- Pruritus
Pruritus
624 reports
- Rash
Rash
597 reports
- Pain 526
Pain
526 reports
- Eczema 447
Eczema
447 reports
- Dermatitis Atopic 421
Dermatitis Atopic
421 reports
- Erythema 370
Erythema
370 reports
- Drug Hypersensitivity 258
Drug Hypersensitivity
258 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Reports over time
Adverse-event reports filed for crisaborole each year to the FDA Adverse Event Reporting System (FAERS).
Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.
Where crisaborole sits
crisaborole has more FDA adverse-event reports than 38% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is crisaborole; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 9,400 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2013–2025.
Total Reports
9,400
Reports Mentioning Death
24
0.3% of reports — not proof of cause
Hospitalization Reports
142
Top Indication
Dermatitis Atopic
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 2 | APPLICATION SITE PAIN | 1,415 |
| 3 | BURNING SENSATION | 985 |
| 5 | CONDITION AGGRAVATED | 699 |
| 6 | PRURITUS | 624 |
| 7 | RASH | 597 |
| 8 | PAIN | 526 |
| 9 | ECZEMA | 447 |
| 10 | DERMATITIS ATOPIC | 421 |
| 11 | ERYTHEMA | 370 |
| 13 | DRUG HYPERSENSITIVITY | 258 |
| 14 | DRY SKIN | 250 |
| 15 | DRUG INEFFECTIVE FOR UNAPPROVED INDICATION | 241 |
| 16 | APPLICATION SITE ERYTHEMA | 234 |
| 17 | SKIN BURNING SENSATION | 231 |
| 18 | THERAPEUTIC PRODUCT EFFECT INCOMPLETE | 219 |
Reactions in Death Reports
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
If you have a hypersensitivity reaction, stop using Eucrisa right away. Signs of a reaction include severe itching, swelling, and redness at the application site or somewhere else on your body.
Common Questions
What should I do if Eucrisa does not seem to be working?
Can I use Eucrisa on any part of my body?
How long should I use Eucrisa?
What should I do if I accidentally swallow Eucrisa?
Can I use other skin products while using Eucrisa?
What are the ingredients in Eucrisa?
How often should I apply Eucrisa?
Can children use Eucrisa?
What should I do if I get Eucrisa in my eyes?
Is it okay to use Eucrisa if I am allergic to similar medications?
What are the common side effects of crisaborole?
What drug class is crisaborole?
What pregnancy or breastfeeding source fields are listed for crisaborole?
Related Medications in PDE4 Inhibitor (Topical)
Other drugs grouped near crisaborole - same-class peers and common alternatives.
adapalene
Differin
Compare with crisaborole →
apremilast
Otezla
Apremilast (Otezla/Otezla XR) is a medicine that can help adults and children manage psoriatic arthritis and psoriasis.
Compare with crisaborole →
azelaic acid
Finacea, Azelex
Azelaic acid gel is a topical medicine that helps treat rosacea.
Compare with crisaborole →
benzoyl peroxide
Benzac, PanOxyl
Benzoyl peroxide is a topical medicine that fights germs on your skin.
Compare with crisaborole →
betamethasone
Diprosone, Luxiq
Betamethasone dipropionate cream is a strong steroid medicine used on the skin.
Compare with crisaborole →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for crisaborole: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 9,400.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 0.26%.
- etonogestrel Δ 0.06 pts · 46,939 reports · Progestin (Implant) 0.20%death share
- levonorgestrel Δ 0.12 pts · 197,074 reports · Progestin 0.14%death share
- dupilumab Δ 0.17 pts · 411,692 reports · Anti-IL-4/IL-13 Monoclonal Antibody 0.43%death share
- adapalene Δ 0.24 pts · 178,147 reports · Retinoid (Topical) 0.02%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on crisaborole
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for crisaborole
The FDA label for crisaborole (sold under brand names such as Eucrisa) classifies it as a prescription-only medication in the PDE4 Inhibitor (Topical) class. Eucrisa treats mild to moderate atopic dermatitis, also known as eczema. Official labeling lists 1 commonly reported side effect, including Pain where you put the medicine.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 9,400 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. NADAC pricing from CMS.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: September 23, 2025
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages